1. 1) Orimo H., “Guideline for Osteoporosis Prevention and Treatment Ver. 2011, Evaluation of fracture risk factors due osteoporosis,” ed. by the Committee of Guideline for Osteoporosis Prevention and Treatment, Lifescience Publishing Co., Ltd., Tokyo, 2011, pp. 38-39.
2. 2) Kanis J. A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., Burckhardt P., Cooper C., Christiansen C., Cummings S., Eisman J. A., Fujiwara S., Glüer C., Goltzman D., Hans D., Krieg M. A., La Croix A., McCloskey E., Mellstrom D., Melton L. J. 3rd, Pols H., Reeve J., Sanders K., Schott A. M., Silman A., Torgerson D., van Staa T., Watts N. B., Yoshimura N., Osteoporos. Int., 18, 1033-1046 (2007).
3. 3) Orimo H. “Guideline for Osteoporosis Prevention and Treatment Ver. 2015, Criteria for initiating drug therapy for primary osteoporosis,” ed. by the Committee of Guideline for Osteoporosis Prevention and Treatment, Lifescience Publishing Co., Ltd., Tokyo, 2015, p. 63.
4. 4) University of Sheffield. “Calculation tool for FRAX.”: 〈https://www.sheffield.ac.uk/FRAX/tool.aspx?country=3〉, cited 1 May, 2018.
5. 5) Yamamoto N., Takeda Y., Hashiba A., Sugihara M., Tsuchiya H., Osteoporosis Jpn., 21, 363-370 (2013).